From the Editor's Desk…
Journal of Hepatology
; 77(1):1-4, 2022.
Article
in English
| EMBASE | ID: covidwho-1895194
heparanase; heparanase 1; hepatitis B core antigen; hepatitis B surface antibody; hepatitis B vaccine; immunosuppressive agent; peginterferon alpha; programmed death 1 receptor; SARS-CoV-2 vaccine; unclassified drug; acute kidney failure; adenosine diphosphate ribosylation; autoimmune hepatitis; bile duct carcinoma; cancer epidemiology; cancer immunotherapy; cancer resistance; chronic hepatitis B; chronicity; coronavirus disease 2019; cost effectiveness analysis; disease duration; disease eradication; fatty acid oxidation; fibrogenesis; gastroenterology; graft recipient; hepatic stellate cell; hepatitis B; hepatitis C; Hepatitis C virus; human; immune evasion; immunosuppressive treatment; infant; inflammation; liver cancer; liver cirrhosis; liver histology; liver transplantation; meta analysis (topic); mitochondrial respiration; nonhuman; note; protein processing; recurrent disease; resting energy expenditure; Taiwan; tumor immunity; upregulation; vaccination; virus hepatitis
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Journal of Hepatology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS